656247-17-5

Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.

Nintedanib-D8 is a deuterated compound of Nintedanib. Nintedanib (T1777) has a CAS number of 656247-17-5. Nintedanib (T1777) is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).

Nintedanib-[13C, D3] (Standard) is a reference standard of Nintedanib-[13C, D3] intended for quantitative analysis, quality control, and related biochemical research applications.

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor targeting VEGFR1/2/3, FGFR1/2/3, and PDGFRα/β.

Nintedanib esylate hemihydrate is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).

Nintedanib-13C-D3 is the 13C and deuterated compound of Nintedanib. Nintedanib (T1777) has a CAS number of 656247-17-5. Nintedanib (T1777) is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).

Nintedanib-13C,D3 is a 13C- and deuterium-labeled version of Nintedanib. Nintedanib (T1777) (BIBF 1120) is a potent triple angiokinase inhibitor that effectively blocks VEGFR1/2/3, FGFR1/2/3, and PDGFRα/β with IC50 values of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM, and 59 nM/65 nM, respectively.